Chemical patent

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in

Retrieved on: 
Monday, March 18, 2024
Neurology, Headache, NDS, Patient, Contraindication, Nonsteroidal anti-inflammatory drug, Chronic pain, Migraine, Health Canada, Chemical patent, PALO, OPML, Patent, Therapy, FDA

ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3

Key Points: 
  • ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3
    The anticipated timeline for approval in Canada is approximately 12 months depending on review cycles and information requests by Health Canada.
  • ELYXYB®’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

Fraser Institute News Release: Federal government’s proposed drug changes mean potentially lower prices but reduced access and innovation

Retrieved on: 
Tuesday, August 16, 2022
GLOBE, PMPRB, Government, Chemical patent, COVID-19, Fraser Institute, Colorado College, Vaccine, Federation, Bangladesh Technical Education Board, Public policy, Economics, Pharmaceutical industry

The Patented Medicines Prices Review Boards (PMPRB) recently announced amendments to the Patented Medicines Regulations.

Key Points: 
  • The Patented Medicines Prices Review Boards (PMPRB) recently announced amendments to the Patented Medicines Regulations.
  • The amendments notably change the group of countries used for comparison to determine drug prices in Canada.
  • These changes will have significant consequences for Canadians because the potential lower prices will discourage pharmaceutical companies from launching new products in Canada.
  • Ottawas proposed changes to drive down drug prices will have an impact on peoples access to new life-saving medicines, and Canadians should be aware of the trade-off the government is making.

JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Pharmaceutical, Health, Oncology, Securities Act of 1933, Chemical patent, Immortalised cell line, Degenerative disease, Business architecture, Person, Annual report, Program, Registration statement, Partnership, Communication, FDA, Laboratoires Pierre Fabre, Acquisition, Oaktree Capital Management, Goal, Sale, U.S. Securities and Exchange Commission, CEO, Solution, Prospectus, SEC, Form, Injection, Terminology, Failure, Patient, Multimedia, Vitamin, NYSE, S.A.S, Compliance, Chinese patent medicine, BLA, Risk, Health Canada, Growth, Name, Cancer, NASDAQ, Forward-looking statement, Register, USD, Review, Business, Osteoporosis, Inflammation, Generic drug, Pharmaceutical industry, Fine chemical, Security (finance), IQVIA, EU, Adalimumab, JAMP Pharma Group, Alvotech, AVT02, JAMP PHARMA GROUP, ALVOTECH, AVT02

JAMP has accordingly been issued notices of compliance for these presentations of SIMLANDI and can launch them in Canada.

Key Points: 
  • JAMP has accordingly been issued notices of compliance for these presentations of SIMLANDI and can launch them in Canada.
  • Mark Levick, CEO of Alvotech, added, We are delighted by the approval from Health Canada, which highlights Alvotechs global approach to biosimilars, and look forward to continued collaboration with JAMP.
  • SIMLANDI is a high-concentration, citrate-free biosimilar to Humira, which is used to treat a range of certain inflammatory conditions.
  • In January 2020, JAMP Pharma Group signed an exclusive agreement with Alvotech to collaborate on a broad portfolio of biosimilars.

Statement from the Minister of Health on the deferral of Coming-into-Force of the Regulations Amending the Patented Medicines Regulations

Retrieved on: 
Thursday, December 23, 2021
Atlantic Canada, Industry, COVID-19, Government of Canada, The Honourable, Chemical patent, Government, Patented Medicine Prices Review Board, Pharmaceutical industry

To bring these amendments into force, in the context of a global pandemic, requires preparedness and consultation.

Key Points: 
  • To bring these amendments into force, in the context of a global pandemic, requires preparedness and consultation.
  • A delay also allows the Government to further engage stakeholders on the application of these amendments within the changing pharmaceutical landscape.
  • The amendments to the Patented Medicines Regulations were the first substantive update to the regulations in more than 30 years.
  • These changes aim to protect Canadian consumers from excessive prices for patented medicines by providing the Patented Medicine Prices Review Board with new tools and additional information.

International Patent Reviews Releases Study on Sun Pharmaceuticals' LEVULAN® KERASTICK® patent

Retrieved on: 
Monday, July 26, 2021
Patent law, Pharmaceuticals policy, Monopoly, Patent, Pharmaceutical industry in China, United States patent law, Chemical patent, Articles, Outline of patents

DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.

Key Points: 
  • DALLAS, July 26, 2021 /PRNewswire/ -- Today, International Patent Reviews, LLC (IPR) released a study on Sun Pharmaceuticals' U.S. Patent No.
  • However, many pharmaceutical filings are purposefully structured to artificially extend the reach of protection afforded by our patent system."
  • IPR has developed a comprehensive and multifaceted process for identifying pharmaceutical patent filings that have taken advantage of the patent system.
  • The first patent for LEVULAN KERASTICK was issued in January of 1992.

Drug Patents in Development Database Service 2021: US & International Patents, Including Active and Expired Patents - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, Pharmaceutical, Life sciences, Pharmaceutical industry, Articles, Health sciences, Chemical patent, Medication, Drug, Biopharmaceutical, Subscription business model, Patent

b'The "Drug Patent Database Subscription: Drugs in Development" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?

Key Points: 
  • b'The "Drug Patent Database Subscription: Drugs in Development" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?
  • Your needs evolve as the industry keeps changing.
  • Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.\nThis subscription for the Drugs in Development portion of the database offers information on:\nGlobal biopharmaceutical markets face constant change.
  • This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches.

United States Drug Patent Litigation Patent Database Service 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 29, 2021
Health, Pharmaceutical, United States patent law, Patent law, Inter partes review, Patent Trial and Appeal Board, Chemical patent, Patent, PTAB, Law, Creativity

b'The "Drug Patent Database Subscription: US Drug Patent Litigation" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?

Key Points: 
  • b'The "Drug Patent Database Subscription: US Drug Patent Litigation" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?
  • Your needs evolve as the industry keeps changing.
  • Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.\nThis subscription for the US Drug Patent Litigation portion of the database offers information on:\nPatent Trial and Appeal Board, PTAB inter partes review, post-grant review\nGlobal biopharmaceutical markets face constant change.
  • This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches.

United States Drug Patent Prices Database 2021: Brand vs. Generic Drug Price Gap, find generic entry opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 28, 2021
Health, Pharmaceutical, Health sciences, Life sciences, Pharmaceutical industry, Pharmacy, Pharmaceutical sciences, Medication costs, Medication, Chemical patent, Subscription business model, Patent, Drug, Biopharmaceutical

b'The "Drug Patent Database Subscription: US Drug Prices" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?

Key Points: 
  • b'The "Drug Patent Database Subscription: US Drug Prices" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?
  • Your needs evolve as the industry keeps changing.
  • Since then dozens of additional datasets have been added by aggressive adaptation based on your needs.\nThis subscription for the US Drug Prices portion of the database offers information on:\nGlobal biopharmaceutical markets face constant change.
  • This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches.

2021 US Drug Patent Database Subscription: Annual Gross Revenues & Units Sold, Prescription Payment Methods, Self-Paid, Private Insurance, Medicaid and Pharmacy Locations & Types - ResearchAndMarkets.com

Retrieved on: 
Friday, April 23, 2021
Health, Pharmaceutical, Patent law, Chemical patent, Patent, Database, Subscription business model, Articles, Marketing

b'The "Drug Patent Database Subscription: US Top Drug Sales" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?

Key Points: 
  • b'The "Drug Patent Database Subscription: US Top Drug Sales" database has been added to ResearchAndMarkets.com\'s offering.\nThis subscription was created to answer a simple question: When do drug patents expire?
  • Your needs evolve as the industry keeps changing.
  • The analyst understands and works together with you to help you make better decisions.
  • This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches.

Detailed United States Drug Prices Database 2020 - Brand vs. Generic Drug Price - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 28, 2020
Health, Pharmaceutical, Health sciences, Pharmaceutical sciences, Pharmacy, Health care, Drug pricing, Patent law, Medication costs, Chemical patent, Patent, Pharmaceutical industry, Subscription business model, Medication

The "Drug Patent Database Subscription: US Drug Prices" database has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug Patent Database Subscription: US Drug Prices" database has been added to ResearchAndMarkets.com's offering.
  • This subscription was created to answer a simple question: When do drug patents expire?
  • This subscription for the US Drug Prices portion of the database offers information on:
    Global biopharmaceutical markets face constant change.
  • What is the earliest generic entry opportunity date for a drug with dozens of patents?